低价股词汇表：制药公司因与诺和诺德达成价值10亿美元的肥胖症协议而飙升-动脉网

Penny Stock Lexicon Pharmaceuticals Surges On Obesity Pact Worth $1 Billion With Novo Nordisk

benzinga 等信源发布 2025-03-28 09:02



可切换为仅中文







Lexicon Pharmaceuticals Inc.

Lexicon制药公司

LXRX

stock is trading higher on Friday.

股票在周五交易走高。

Penny stock Lexicon Pharmaceuticals entered into an exclusive license agreement with

便士股票Lexicon Pharmaceuticals与

Novo Nordisk A/S

诺和诺德公司

NVO

on Friday for LX9851, a first-in-class, oral non-incretin development candidate in obesity and

周五，LX9851 在肥胖症和

associated metabolic disorders

Also Read:

另请阅读：

Lexicon Pharmaceuticals (LXRX) Stock Is Down: What’s Going On?

Lexicon制药公司（LXRX）股票下跌：发生了什么？

Lexicon will be responsible for completing the agreed-upon Investigational New Drug (IND) application-enabling activities for LX9851.

Lexicon 将负责完成 LX9851 商定的新药临床试验（IND）申请相关活动。

Novo Nordisk will file the IND and all further development, manufacturing, and

诺和诺德将提交IND并进行所有进一步的开发、制造和

commercialization of LX9851

LX9851的商业化

。

Lexicon is eligible to receive upfront and near-term milestone payments of up to $75 million. In total, Lexicon will be eligible to receive $1 billion in upfront and potential development, regulatory and sales milestone payments. Lexicon is also entitled to tiered royalties on net sales of LX9851.

Lexicon有资格获得高达7500万美元的首付款和近期里程碑付款。总计下来，Lexicon将有资格获得高达10亿美元的首付款及潜在的开发、监管和销售里程碑付款。此外，Lexicon还有权获得LX9851净销售额的阶梯式专利使用费。

LX9851, discovered and developed by Lexicon, is a potent and selective oral small molecule inhibitor of Acyl-CoA Synthetase 5 (ACSL5).

LX9851是由Lexicon发现和开发的一种有效且选择性的酰基辅酶A合成酶5（ACSL5）口服小分子抑制剂。

ACSL5 plays a key role in the metabolic pathway, which regulates fat accumulation and energy balance.

ACSL5在调节脂肪积累和能量平衡的代谢途径中起关键作用。

Additionally, LX9851 may activate the ileal brake mechanism leading to increased satiety by delaying gastric emptying and suppressing appetite. Preclinical in vivo efficacy data presented at

此外，LX9851可能通过延迟胃排空和抑制食欲来激活回肠制动机制，从而增加饱腹感。临床前体内功效数据在会议上展示。

Obesity Week 2024

2024年肥胖周

show that LX9851, when combined with Novo Nordisk’s semaglutide, significantly reduced weight, food intake and fat mass compared to semaglutide alone.

结果显示，与单独使用诺和诺德的司美格鲁肽相比，LX9851 与司美格鲁肽联合使用时显著减轻了体重、食物摄入量和脂肪量。

Separately, LX9851 mitigated weight regain and had positive effects on liver steatosis when introduced after semaglutide discontinuation.

单独来看，LX9851在司美鲁肽停用后引入时，减轻了体重反弹，并对肝脂肪变性产生了积极影响。

Price Action:

价格行为:

LXRX stock is up 97.4% at $0.69 during the premarket session at the last check Friday.

LXRX股票在上周五最后一次检查时，盘前交易时段上涨了97.4%，达到0.69美元。

Read Next:

接下来阅读：

Microsoft Plans Proprietary AI To Power Business Software And Reduce OpenAI Dependence: Report

微软计划开发专有人工智能以增强商业软件并减少对OpenAI的依赖：报告

Photo: Shutterstock